Today the Institute for Clinical and Economic Review (ICER) announced that it will assess the comparative clinical effectiveness and value of aducanumab (Biogen) for treatment of Alzheimer’s disease. The assessment will be publicly discussed in May 2021 during a meeting of the California Technology Assessment Forum (CTAF), where the review panel will consider the evidence presented in ICER’s report before voting on the matter. The FDA is expected to make a ruling on aducanumab in early 2021.
Timelines of key posting dates and public comment periods for this assessment are provided on ICER’s website. An Open Input period begins today and is intended to allow stakeholders to share key information relevant to the development of the evidence report. Comments will be accepted from all interested stakeholders until October 16, 2020 at 5 p.m. ET. During this time, ICER will contact key patient groups and clinical experts to gain further insights on the patient perspective and clinical context of treating Alzheimer’s disease. Find more information on the Open Input period here.